GSK linked to Allergan takeover
pharmafile | March 26, 2009 | News story | Sales and Marketing |Â Â Allergan, GSKÂ
GlaxoSmithKline may be considering a bid to buy Allergan, the company behind 'cosmaceutical' products such as Botox.
Analysts have seized on speculation in the Wall Street Journal that GSK may make a move for the specialist company, with suggestions that it will pay around $19 billion.
Shares in Allergan gained 20% in the last few days as rumours have mounted over a bid from the pharma giant.
A buy-out of the fast-growing company, which also has a strong ophthalmology division, would be in line with GSK's declared strategy of diversification and smaller-scale acquisitions.
The companies already have a relationship – they launched a partnership in October 2005 in which GSK is developing and promoting Botox in Japan and China.
Probably the world's best known non-surgical cosmetic product, Botox earns in excess of $1billion a year and is forecast for further growth with expansion into the Asian markets.
GSK has been promoting the product since 2006 and is now ready to launch Botox for the treatment of glabellar lines (deep lines between the eyebrows) in Japan during the first quarter of this year.
GSK pays Allergan royalties on Botox sales in Japan and China and fixed and performance payments on the migraine drugs.
As part of the same co-marketing deal, Allergan co-promotes GSK's migraine treatments Imitrex and Amerge in the US.
Related Content
GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …
Multiple myeloma treatment approved in Japan
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and …
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
PHILADELPHIA–GSK plc today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination …
